CABALETTA BIO, INC.
Ownership & governance
Executives 5Directors 6Avg age 61Avg tenure 6.4y
SN
Steven Nichtberger
Chief Executive Officer
Age 64Since 2017-03-31Profile →
+10
Executives5
SN
Steven Nichtberger→
Chief Executive Officer
Age 64Since 2017-03-31
AM
Anup Marda→
Director of Finance/CFO
Age 48Since 2018-12-31
QY
Qing Sarah Yuan→
Chief Tech/Sci/R&D Officer
Age 55Since 2024-05-31
HH
Heather Harte-Hall→
Compliance Officer
—Since 2019-02-28
SB
Samik Basu→
Chief Tech/Sci/R&D Officer
—Since 2021-11-08
Board of directors6
SN
Steven Nichtberger→
Chairman
Age 64Since 2017-03-31
MS
Mark Simon→
Director/Board Member
Age 64Since 2018-09-30
RH
Richard Henriques→
Director/Board Member
Age 70Since 2019-02-18
CB
Catherine Bollard→
Director/Board Member
Age 58Since 2019-04-01
SB
Scott Brun→
Director/Board Member
Age 58Since 2021-06-23
ST
Shawn Tomasello→
Director/Board Member
Age 67Since 2023-07-20
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Jennison Associates LLC | 26.53 % | 24,267,980 |
| T. Rowe Price Investment Management, Inc. | 12.11 % | 11,080,005 |
| Bain Capital Life Sciences LP | 10.58 % | 9,677,125 |
| Jennison Associates LLC | 9.808 % | 8,970,578 |
| Adage Capital Partners GP LLC | 9.654 % | 8,829,758 |
Catalog · 2026-07-09
Registry officers11
| Name | Role | Since | Shares |
|---|---|---|---|
| Anup Marda | Director of Finance/CFO | 2018-12-31 | - |
| Qing Sarah Yuan | Chief Tech/Sci/R&D Officer | 2024-05-31 | - |
| Samik Basu | Chief Tech/Sci/R&D Officer | 2021-11-08 | - |
| Steven Nichtberger | Chief Executive Officer | 2017-03-31 | - |
| Steven Nichtberger | Chairman | 2017-03-31 | - |
| Catherine Bollard | Director/Board Member | 2019-04-01 | - |
| Mark Simon | Director/Board Member | 2018-09-30 | - |
| Richard Henriques | Director/Board Member | 2019-02-18 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus noneMean target 13.25Range 3–30Analysts 8
3Mean 13.2530
- Strong buy 1
- Buy 7
- Hold 2
Broker actions40 of 85
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | 16 | 2026-09-01 |
| Wells Fargo | Maintained | Equal-Weight | 3 | 2026-08-14 |
| Wells Fargo | Maintained | Equal-Weight | 4 | 2026-05-15 |
| Cantor Fitzgerald | Reiterated | Overweight | 30 | 2026-05-04 |
| Morgan Stanley | Maintained | Overweight | 13 | 2026-03-24 |
| Guggenheim | Maintained | Buy | 16 | 2026-03-24 |
| Cantor Fitzgerald | Maintained | Overweight | 30 | 2025-10-31 |
| HC Wainwright & Co. | Reiterated | Buy | 16 | 2025-10-10 |
| Cantor Fitzgerald | Reiterated | Overweight | 15 | 2025-09-05 |
| Citigroup | Maintained | Buy | 10 | 2025-08-14 |
| Wells Fargo | Maintained | Equal-Weight | 2 | 2025-08-08 |
| Guggenheim | Maintained | Buy | 15 | 2025-08-08 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.